Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Sep 10, 2024 4:16pm
184 Views
Post# 36217318

RE:Andrey Omelchak - BNN - TOP PICK

RE:Andrey Omelchak - BNN - TOP PICKA successful investor once told me some stocks stay significantly undervalued for a long time, the market fails to recognize them for whatever reason... and eventually they just get acquired. I've actually been thinking about this quite a bit lately. Knight certainly fits that description.

With that said, my impression of Goodman is he won't be selling for a cheap price, so the multiple has to be meaningful in this case. They still have plenty of moves to make, and the business is only starting to pick up.

Liked the analysis. In the video, he says "tremendous margin expansion opportunity that nobody's talking about..." well, it's been mentioned here. :D Also, agreed about the liquidity of the stock.
<< Previous
Bullboard Posts
Next >>